Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Move over Tregs, MDSCs are here.

John W Semple1

  • 1ST. MICHAEL'S HOSPITAL.

Blood
|March 26, 2016
PubMed
Summary
This summary is machine-generated.

This study reveals myeloid-derived suppressor cells (MDSCs) in immune thrombocytopenia (ITP) pathogenesis. High-dose dexamethasone (HD-DXM) boosts MDSC function, increasing platelet counts.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding immune thrombocytopenia pathophysiology has come a long way.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Toggling STAT to restore T-cell homeostasis in ITP.

Blood·2026
Same author

MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia.

British journal of haematology·2026
Same author

Circulating T follicular helper cells as emerging biomarkers in pediatric Evans syndrome.

Haematologica·2026
Same author

Platelet transcriptomics sense disease states.

EBioMedicine·2026
Same author

Platelet glycoprotein V autoantibodies and complement C3 are associated with thrombosis in systemic lupus erythematosus.

Haematologica·2026
Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026
Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026
Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026
Same journal

Precision Transfusion Medicine in the Omics Era.

Blood·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
See all related articles

Area of Science:

  • Immunology
  • Hematology
  • Pathogenesis of ITP

Background:

  • Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
  • The role of specific immune cells in ITP pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the involvement of myeloid-derived suppressor cells (MDSCs) in immune thrombocytopenia (ITP).
  • To identify the mechanism by which high-dose dexamethasone (HD-DXM) impacts MDSCs and platelet counts in ITP.

Main Methods:

  • Analysis of MDSC populations in ITP patients.
  • Assessment of MDSC function in response to HD-DXM treatment.
  • Correlation of MDSC levels and function with platelet counts.

Main Results:

Related Experiment Videos

  • MDSCs are implicated in the pathogenesis of immune thrombocytopenia (ITP).
  • High-dose dexamethasone (HD-DXM) significantly promotes MDSC expansion and enhances their function.
  • Increased MDSC activity correlates positively with elevated platelet counts in ITP patients.

Conclusions:

  • MDSCs play a critical role in the development and progression of ITP.
  • HD-DXM exerts therapeutic effects in ITP by modulating MDSC activity.
  • Targeting MDSCs represents a potential therapeutic strategy for ITP.